Doxorubicin Plus Trabectedin May Be Effective for Uterine, Soft-Tissue Leiomyosarcoma

Share this content:
Doxorubicin plus trabectedin have activity as first-line treatment for uterine leiomyosarcoma and soft-tissue leiomyosarcoma.
Doxorubicin plus trabectedin have activity as first-line treatment for uterine leiomyosarcoma and soft-tissue leiomyosarcoma.

According to a recent study published online in the journal The Lancet Oncology, researchers have found that doxorubicin plus trabectedin have activity as first-line treatment for uterine leiomyosarcoma and soft-tissue leiomyosarcoma.

Researchers sought to investigate the effect of first-line doxorubicin and trabectedin on disease control and survival in patients with metastatic leiomyosarcoma of uterine or soft-tissue origin in a single-group, multicenter, phase 2 study.

Researchers enrolled and treated 109 patients with doxorubicin 60mg/m2 intravenously and trabectedin 1.1mg/m2 intravenously on day 1, and pegfilgrastim 6mg subcutaneously on day 2, every 3 weeks for up to six cycles.

RELATED: Reduced Target Volume Significantly Reduces Late Toxicities in Extremity Sarcoma

Ultimately, 68% of those with uterine leiomyosarcoma and 74% of those with soft-tissue leiomyosarcoma received all six cycles. Results showed that 59.6% of patients with uterine disease achieved a partial response, 27.7% had stable disease, and 87.2% achieved disease control.

Of those with soft-tissue disease, 3.3% achieved a complete response, 36.1% achieved a partial response, 52.5% had stable disease, and 91.8% achieved disease control.

In regard to safety, the most common severe adverse events were neutropenia, alanine aminotransferase elevation, thrombocytopenia, anemia, febrile neutropenia, and fatigue. The authors conclude that this drug combination should be developed further in a phase 3 study compared to the standard of care in this patient population.

Reference

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters